NYSE · MDT
Healthcare · Medical - Devices
$93.75
Down-$0.05 (-0.05%)
Updated Sep 16, 2026, 10:52 AM
SID Score
6.5/10
Composite research score
Smart Money
34/100
Bearish
Price performance
1M range · 20 trading sessions · Daily adjusted prices
MDT closed at $93.75 after 20 trading sessions, up 1.80% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $93.69 | $94.70 | $92.73 | $93.75 | 7.15M |
| Sep 14, 2026 | $93.35 | $94.075 | $92.73 | $93.80 | 9.26M |
| Sep 11, 2026 | $93.00 | $93.00 | $90.26 | $90.96 | 5.41M |
| Sep 10, 2026 | $92.00 | $92.535 | $90.58 | $91.62 | 5.12M |
| Sep 9, 2026 | $92.39 | $93.39 | $91.75 | $91.89 | 7.73M |
| Sep 8, 2026 | $93.25 | $93.30 | $91.42 | $92.39 | 8.2M |
| Sep 4, 2026 | $92.76 | $94.74 | $92.31 | $94.17 | 9.01M |
| Sep 3, 2026 | $93.04 | $93.72 | $90.965 | $93.10 | 7.41M |
| Sep 2, 2026 | $92.25 | $94.605 | $91.47 | $92.18 | 9.16M |
| Sep 1, 2026 | $94.00 | $95.41 | $90.80 | $92.04 | 18.84M |
| Aug 31, 2026 | $90.75 | $91.12 | $90.04 | $90.65 | 12.63M |
| Aug 28, 2026 | $90.29 | $91.56 | $89.94 | $91.23 | 6.47M |
| Aug 27, 2026 | $91.50 | $91.61 | $89.96 | $89.97 | 7.77M |
| Aug 26, 2026 | $91.08 | $92.53 | $90.75 | $92.02 | 6.05M |
| Aug 25, 2026 | $92.275 | $92.82 | $91.11 | $91.14 | 6.8M |
| Aug 24, 2026 | $93.43 | $94.05 | $92.655 | $92.90 | 6.01M |
| Aug 21, 2026 | $92.57 | $93.55 | $91.73 | $93.35 | 7.49M |
| Aug 20, 2026 | $93.37 | $94.53 | $92.23 | $92.30 | 6.35M |
| Aug 19, 2026 | $92.38 | $94.715 | $91.95 | $94.13 | 5.64M |
| Aug 18, 2026 | $92.00 | $93.09 | $91.4652 | $92.09 | 6.79M |
The latest Smart Investors Daily articles mentioning MDT.
MDT research
Company profile and research snapshot.
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 3, 2026 | UBS | Buy | — |
| Sep 2, 2026 | Truist Securities | Hold | — |
| Sep 2, 2026 | Wells Fargo | Overweight | — |
| Sep 2, 2026 | RBC Capital | Outperform | — |
| Sep 2, 2026 | B of A Securities | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 11, 2026
On September 1, MiniMed (NASDAQ:MMED) reported its first full quarter as a stand-alone public company, and the numbers suggest the split from Medtronic is already paying off. Revenue jumped 15.8% to $843 million, and management raised its full-year growth outlook just months after the IPO roadshow. The catalyst is simple. A new pump finally shipped, […]
Yahoo · Sep 10, 2026
Jim Cramer called Medtronic plc (NYSE:MDT) a “quandary” on the September 8 episode of Mad Money, as he said: At the same time, there’s some tremendous healthcare companies in bull market mode… Here’s one that’s a quandary, Medtronic. Medtronic, the medical device company, shocked us with a big upside surprise and a major increase in […]
Yahoo · Sep 10, 2026
On September 1, Medtronic (NYSE:MDT) reported fiscal 2027 first-quarter results that blew past its own guidance, with revenue of $9.8 billion and organic growth of 13.7%. An extra selling week included in the quarter, which ended July 31, added roughly $570 million to that figure. Still, even stripping that out, management called it the strongest […]
Yahoo · Sep 9, 2026
Medtronic plc (NYSE:MDT) entered fiscal 2027 expecting solid growth. One quarter later, strong demand for its cardiovascular devices has given management enough confidence to raise that outlook. The company increased its organic revenue growth forecast and lifted the lower end of its adjusted earnings range after beating quarterly expectations. Its cardiovascular business was the standout, […]
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MDT.
